Arrhythmia Market Report 2025

The arrhythmia market size has grown strongly in recent years. It will grow from $7.8 billion in 2024 to $8.35 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increased lifestyle-related risk factors, rise in cardiovascular diseases, improvements in implantable devices, global increase in cardiac surgery, growing demand for remote monitoring, research and development in antiarrhythmic drugs.

The arrhythmia market size is expected to see strong growth in the next few years. It will grow to $11.83 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to expanding awareness and education, personalized medicine approaches, expansion of electrophysiology labs, focus on early detection and prevention, genetic screening for familial arrhythmias, healthcare infrastructure development. Major trends in the forecast period include advancements in cardiac monitoring technologies, telehealth and remote patient monitoring, focus on atrial fibrillation (AF) detection and management, implantable devices for arrhythmia management, innovations in ECG monitoring devices, regulatory focus on medical device approvals.

The rising prevalence of cardiac diseases and other heart problems is expected to significantly drive the growth of the arrhythmia market in the coming years. Cardiac disease, or cardiovascular disease, encompasses a wide range of heart and blood vessel conditions, including atherosclerosis, heart attacks, strokes, and arrhythmias. Both functional defects, such as diastolic and systolic dysfunction, and electrical defects, including the emergence of arrhythmias, contribute to a high incidence of heart failure, atrial fibrillation, and other cardiovascular diseases. For example, a report from the CDC (Centers for Disease Control and Prevention) in October 2022 revealed that there are approximately 69,700 heart disease-related deaths and 80,500 heart attacks annually in the United States. This alarming prevalence of cardiac conditions underscores the growing demand for arrhythmia management and treatment solutions, thereby propelling the growth of the arrhythmia market.

The escalating presence of an aging population emerges as a key catalyst driving the trajectory of the arrhythmia market. The demographic shift towards an increasingly elderly population fuels the demand for diagnostic and therapeutic approaches to manage arrhythmias, given that aging is a significant risk factor for irregular heart rhythms. This demographic trend emphasizes the necessity for innovative technologies and treatments within the arrhythmia market, fostering research, development, and market penetration of medical interventions tailored to address the distinctive healthcare needs of the elderly. As projected by the World Health Organization in October 2022, by 2030, one in six individuals globally will be 60 years or older, with the population of individuals aged 60 and above expected to rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Hence, the aging demographic exerts a profound influence driving the arrhythmia market's growth trajectory.

New treatment therapies represent a significant trend in the arrhythmia market. Key players in the industry are focused on developing innovative therapies, such as cryoablation therapy, which is specifically designed for patients with arrhythmias. For example, in August 2023, GE HealthCare, a US-based medical technology firm, launched CardioVisio for Atrial Fibrillation. This digital, patient-centric clinical decision support tool aims to facilitate precision care. CardioVisio utilizes advanced data analytics and patient insights to assist healthcare professionals in understanding and managing atrial fibrillation, a prevalent heart condition. By providing personalized care plans and real-time data tracking, this tool seeks to enhance the accuracy of treatment decisions and improve patient outcomes, marking a significant advancement in cardiac care management.

Prominent entities within the arrhythmia market are actively engaged in the development of cutting-edge catheters to fortify their positions within the industry. Catheters, being slender, flexible tube-like medical devices, play diverse roles such as extracting fluids from body cavities, administering fluids or medications, or measuring various parameters within the body. For instance, in July 2023, Biosense Webster, Inc., a US-based medical equipment manufacturer, unveiled the Optrell Mapping Catheter, incorporating TrueRef Technology, engineered to assist electrophysiologists in mapping intricate cardiac arrhythmias. This catheter integrates a fixed array of small electrodes, enabling high-definition mapping for conditions like atrial fibrillation and tachycardia. Specifically designed for compatibility with the Carto 3 system developed by Biosense Webster, this catheter expedites the identification of ablation targets with enhanced efficiency and accuracy. By providing heightened diagnostic insights, it significantly boosts confidence in detecting ablation targets even within the most complex cases, marking a substantial advancement in the realm of cardiac electrophysiology.

In a significant move during August 2022, Medtronic, an Ireland-based healthcare technology giant, acquired Affera for an undisclosed sum. This strategic acquisition by Medtronic adds a cardiac ablation portfolio to its offerings, inclusive of the company's inaugural cardiac mapping and navigation technology, enhancing its capacity to cater to patients grappling with cardiac arrhythmias. Affera, a US-based medical technology firm, specializes in delivering innovative solutions for the treatment of cardiac arrhythmias. The inclusion of Affera's expertise and technology within Medtronic's portfolio signifies a noteworthy step forward in augmenting Medtronic's capabilities in providing advanced solutions for managing cardiac arrhythmias, reinforcing its foothold within the arrhythmia market.

Major companies operating in the arrhythmia market are Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, AliveCor Inc., Biotronik SE & Co. KG, Biotricity Inc., GE Healthcare, Koninklijke Philips N.V., Nihon Kohden Corporation, Spacelabs Healthcare, Welch Allyn Inc., Mylan N.V., Lepu Medical Technology Co. Ltd., iRhythm Technologies Inc., BioTelemetry Inc., Fukuda Denshi Co. Ltd., Smart Solutions Technologies Inc., Biosense Webster Inc., Cardiac Science Corporation, CardioComm Solutions Inc., CardioNet LLC, NUUBO SMART SOLUTIONS S.L., Cardiva Medical Inc., Osypka AG, Johnson & Johnson Services Inc., Pfizer Inc, Teva Pharmaceutical Industries Ltd, Applied Cardiac Systems, Acutus Medical, EP Solutions SA.

North America was the largest region in the arrhythmia market in 2024. The regions covered in the arrhythmia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arrhythmia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Arrhythmia is a heart disorder characterized by an abnormality in the normal sequence of electrical impulses, leading to changes in the rate or rhythm at which the heart beats. This can result in the electrical impulses being too fast, too slow, or occurring erratically, leading to irregular heartbeats.

The main types of arrhythmias include supraventricular tachycardias, ventricular arrhythmias, bradyarrhythmias, and others. Supraventricular tachycardias involve a condition where the heart suddenly beats much faster than normal, followed by an abrupt slowing down. Various diagnostic tools, such as an electrocardiogram (ECG) and holter monitor, can be employed to test for arrhythmias. These tests can detect different degrees of heart blocks, including first-degree, second-degree, and third-degree blocks. Arrhythmia-related services are typically provided through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The arrhythmia market research report is one of a series of new reports that provides arrhythmia market statistics, including arrhythmia industry global market size, regional shares, competitors with an arrhythmia market share, detailed arrhythmia market segments, market trends and opportunities, and any further data you may need to thrive in the arrhythmia industry. This arrhythmia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arrhythmia market includes revenues earned by entities from sinus bradycardia, premature atrial contractions (PACS), wandering atrial pacemakers, atrial tachycardia, multifocal atrial tachycardia, atrial flutter, and atrial fibrillation (AFIB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.